Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to $124.1 million.

  • Vanda Pharmaceuticals' Total Non-Current Liabilities rose 3121.41% to $124.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.1 million, marking a year-over-year increase of 3121.41%. This contributed to the annual value of $108.1 million for FY2024, which is 1411.57% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Total Non-Current Liabilities of $124.1 million as of Q3 2025, which was up 3121.41% from $128.4 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Total Non-Current Liabilities registered a high of $128.4 million during Q2 2025, and its lowest value of $72.9 million during Q1 2021.
  • Its 5-year average for Total Non-Current Liabilities is $98.6 million, with a median of $99.8 million in 2024.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 3770.87% in 2022, then tumbled by 907.85% in 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $84.5 million in 2021, then increased by 18.67% to $100.2 million in 2022, then fell by 5.53% to $94.7 million in 2023, then increased by 14.12% to $108.1 million in 2024, then grew by 14.83% to $124.1 million in 2025.
  • Its last three reported values are $124.1 million in Q3 2025, $128.4 million for Q2 2025, and $111.3 million during Q1 2025.